Acute lymphoblastic leukemia (ALL) is a clonal expansion of cells committed into the lymphoid lineage, and, thus, ALL cells express cell surface antigens that are present at discrete stages of normal lymphoid precursors. It has been reported that 5-30% of childhood ALLs express so-called myeloid antigens such as CD11b, CD13, CD14, CD15 and CD33. 1, 2 As representatively shown in reference no. 1, studies in the early 1990s showed the association of myeloid antigen expression with poor prognosis in childhood ALL. Although subsequent studies, as representatively shown in reference no. 2, failed to confirm the prognostic significance of myeloid antigen expression in childhood ALLs that were treated with intensified chemotherapeutic regimens, a later study by the BFM group showed that expression of CD33, but not other myeloid antigens, was an independent poor prognostic factor for childhood B-precursor ALL. 3 The expression of these myeloid antigens on ALL cells has generally been speculated to reflect either misprogramming of differentiation or neoplastic transformation of the particular lymphoid progenitors that co-express myeloid antigens. However, the precise mechanism of myeloid antigen expression in ALL cells largely remains unclarified. t(17;19)-positive ALL has unique characteristics such as frequent presentation of intravascular coagulopathy and hypercalcemia, and has an extremely poor prognosis. 4 Among seven t(17;19)-ALL cases accumulated in Japan, six cases (85.7%) showed surface CD33 expression (Figures 1a and b) , whereas only two cases (28.6%) showed CD13 expression. In addition, 3 of 4 t(17;19)-ALL cell lines (Endo-kun, YCUB-2, and UOC-B1) moderately expressed CD33 (Figure 1c ), whereas none of these lines expressed surface CD13. Real-time RT-PCR revealed that CD33 mRNA expression levels in ALL cell lines correlated with CD33 expression on the cell surface (Figure 1d ), and that CD33 mRNA expression levels in t(17;19)-ALL lines were relatively high in comparison with other types of ALL, with one exception (HAL-01).
In t(17;19)-ALL, the transactivation domain of E2A is fused to the DNA-binding and dimerization domain (bZIP) of HLF, 5 resulting in expression of E2A-HLF fusion transcription factor. Interestingly, HAL-01 cells express E2A-HLF protein with a point mutation causing substitution of isoleucine (I)-526 to phenylalanine (F) in the bZIP domain of HLF that considerably reduces the DNA-binding activity of E2A-HLF, suggesting that intact E2A-HLF transactivates transcription of CD33. To test this, E2A-HLF was inducibly expressed using a Zn-inducible vector in Reh, a CD33-negative pre-B ALL line that expresses CD33 mRNA at an approximately 100-fold lower level than UOC-B1 ( Figure 1d ). In two independent clones (Reh E2A-HLF no. 5 and no. 8), both of which expressed E2A-HLF induced by Zn at an equivalent level to that in UOC-B1 (Figure 2a, lanes 5 and 7) , the levels of CD33 mRNA were over 100-fold higher than that in wild-type Reh (Figure 2b ) and cell surface expression of CD33 became detectable (Figure 2c ). Induction of CD33 mRNA by more than 100-fold was also observed in 697 E2A-HLF cells (Figure 2e ), in which E2A-HLF was induced by Zn at an equivalent level to that in UOC-B1 (Figure 2d) . A reporter assay of the CD33 gene promoter using 697 E2A-HLF cells revealed that the promoter activity of the À839/ þ 508 fragment, which was reported to be active in myeloid cells, 6 was significantly upregulated by Zn (Figure 2f ), indicating that E2A-HLF upregulates transcription of the CD33 gene. It was confirmed that introduction of E2A-HLF induced CD33 mRNA and cell surface protein expression in Nalm6, a B-precursor ALL cell line (Supplementary Figure S1) . It is interesting to note that in Reh E2A-HLF no. 8, neither cell surface expression of CD11b, CD13, CD14 and CD15 (Supplementary Figure S2a) nor cytoplasmic expression of myelo-peroxidase (MPO) (data not shown) was upregulated in the presence of zinc. Although cell surface expression of CD10 and HLA-DR was moderately downregulated, cell surface expression of B-cell-related antigens including CD19, CD22 and CD24 was maintained (Supplementary Figure S2b) . These observations indicate that E2A-HLF is responsible for ectopic CD33 expression in t(17;19)-ALL cells. To the best of our knowledge, this is the first report showing that a fusion protein derived from chromosomal translocation is involved in expression of myeloid antigens on ALL cells.
To further clarify the mechanism by which E2A-HLF induces CD33 gene expression, a panel of E2A-HLF mutants (DAD1/ DLH, IF, BX) was tested (Supplementary Figure S3a) . Each mutant was expressed in Reh cells induced by Zn at an almost equivalent level to that of intact E2A-HLF in UOC-B1 (Supplementary Figure S3b) . EMSA using an oligonucleotide containing the consensus binding sequence of HLF (HLF-CS) as a probe (Supplementary Figure S3c) confirmed the similar DNAbinding activity of DAD1/DLH, which lacks two transactivation domains of E2A, but has the intact bZIP domain, compared with that of E2A-HLF. However, both the IF mutant, which carries a point mutation leading to amino acid substitution I-532 4F in the bZIP of HLF, equivalent to the mutation in E2A-HLF of HAL-01 cells, and basic region mutant (BX), which contains substitutions of critical amino acids in the basic region of HLF showed reduced binding activities to the HLF-CS probe. Unlike wild-type E2A-HLF, the mRNA level of CD33 was not upregulated by induction of BX, IF, or DAD1/DLH mutant (Supplementary Figure S3d) , indicating that both the DNAbinding and transactivation abilities of E2A-HLF are required for induction of CD33 expression.
CD33 is a transmembrane glycoprotein recognizing sialic acids and has two conserved immunoreceptor tyrosine-based inhibition motif-like motifs in its cytoplasmic tail, which are assumed to be involved in cellular signalings. In myeloid cell lines, it has been reported that CD33 is phosphorylated at tyrosine residues when treated with pervanadate, a phosphatase inhibitor, and that tyrosine-phosphorylated CD33 recruits protein-tyrosine phosphatases such as SHP-1 and SHP-2. 7 Thus, tyrosine phosphorylation of CD33 and recruitment of proteintyrosine phosphatases were tested by immunoprecipitation using pervanadate-treated Endo-kun cells, and HL60, a CD33-positive myeloid cell line as a positive control. Immunoblot analysis using anti-CD33 (Figure 3a , left panel) and antiphosphotyrosine ( Figure 3a , right panel) antibodies of the immunoprecipitates generated by anti-CD33 mAb, showed tyrosine phosphorylation of CD33 in both the Endo-kun and HL60 cells. In HL60 cells, SHP-1 was detected in the immunoprecipitates generated by CD33 antibody (Figure 3b , lanes 1 and 2). In contrast, despite the considerable expression of SHP-1 in whole cell lysate of Endo-kun cells (lanes 7 and 8), immunoblot analysis using anti-SHP-1 antibody failed to detect SHP-1 in the immunoprecipitate generated by anti-CD33 of Endo-kun cells (lanes 3 and 4). Association of SHP-2 with CD33 was detected neither in Endo-kun nor in HL60 cells (data not shown). These results suggest that although the CD33 expressed on t(17;19)-ALL cells is tyrosine-phosphorylated and therefore assumed to be functional, CD33 may recruit phosphatases other than SHP-1/SHP-2.
Considering the dismal outcome of conventional chemotherapy for t(17;19)-ALL cases, 4 the development of new therapeutic modalities for t(17;19)-ALL is urgent. We tested gemtuzumab ozogamicin (GO; CMA-676, Mylotarg), a calicheamicin-conjugated humanized anti-CD33 mAb that has anti-leukemic activity against CD33-positive AML cells in vitro and in vivo. 8 As expected, GO induced cell death of HL60 cells in a dose-dependent fashion, but did not affect the survival of Reh cells (Figure 3c , open circles). Among four t(17;19)-ALL lines, GO effectively induced cell death of Endo-kun cells, which strongly expressed CD33 (Figure 1c) but not YCUB-2, which only modestly expressed CD33. As P-glycoprotein reduces sensitivity to GO by causing the efflux of calicheamicin, the cytotoxic activity of GO was tested in the presence of of GO did not induce cell death of wild type Reh cells regardless of pre-incubation with Zn or co-treatment with CSA. In contrast, GO induced cell death of Reh E2A-HLF no. 8 cells to approximately 80% of the cells after pre-incubation with Zn, but to only approximately 20% of the cells after pre-incubation without Zn. Moreover, co-treatment with CSA significantly enhanced the cytotoxic activity of GO against Reh E2A-HLF no. 8 cells that had been pre-treated with Zn. These observations suggest that GO in combination with CSA is an attractive modality for the treatment of t(17;19)-ALL strains that express CD33 at high levels. In summary, these observations show that the CD33 gene is one of the target genes of E2A-HLF chimeric transcription factor derived from translocation. Further analysis is required to elucidate the roles of CD33 in the leukemogenesis of ALL.
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The authors declare no conflict of interest. Imatinib is very effective in controlling BCR-ABL-expressing leukemias, but resistance remains a concern and has led to the development of additional agents with unique activity against BCR-ABL and imatinib-resistant disease. A compound with a novel mechanism of action, ON012380, was recently described that inhibited both wild-type and T315I mutant BCR-ABL. 1 The distinct mechanism of action was of potential clinical significance since the evidence of activity against both unmutated and T315I-mutant BCR-ABL kinase activity and efficacy against T315I-BCR-ABL cells in animal studies were described. However, although BCR-ABL-directed kinase inhibition was described in detail with isolated enzyme, there was only limited information regarding the effects of this compound on BCR-ABL activity in intact cells and in chronic myeloid leukemia (CML) patient specimens.
To further characterize this compound, we synthesized (Supplementary Text File 1, Supplementary Figure 1 ) and characterized (Supplementary Figure 2) ON012380 and compared its activity with that of imatinib and dasatinib. We first examined its specificity and efficacy on interleukin (IL)-3-dependent and BCR-ABL-transformed (unmutated or T315I-mutant) BaF3 cells. As shown in Figure 1a , both imatinib and dasatinib reduced the viability of BaF3 cells transformed by wild-type BCR-ABL but did not affect the viability of IL-3-dependent BaF3 cells or those transformed with T315I-BCR-ABL. In contrast, ON012380 not only reduced the viability of BaF3 cells transformed with either unmutated or T315I-BCR-ABL, but also reduced the viability of IL-3-dependent BaF3 cells. These results suggested that the antitumor activity of ON012380 was not solely dependent on BCR-ABL kinase inhibition.
The effects of ON012380 on BCR-ABL signaling and activation of caspase cascades were also compared with imatinib in IL-3-dependent and BCR-ABL-transformed BaF3 cells. Lysates were collected from cells treated with these compounds for 2 or 24 h and probed for early (2 h) changes in Stat5 and CrkL tyrosine phosphorylation and activation of caspase cascades (24 h). In BCR-ABL-transformed cells, imatinib suppressed both CrkL and Stat5 phosphorylation, whereas ON012380 had only minor effects on these substrates after 2 (Figure 1b ) or 24 h (data not shown). Both compounds induced poly (ADP-ribose) polymerase (PARP) cleavage (24 h). Although neither Stat5 nor CrkL were highly tyrosine phosphorylated or modulated by inhibitors in IL-3-dependent BaF3 cells, PARP cleavage was activated in ON012380-treated cells. These results suggest that ON012380-induced apoptosis was not dependent on BCR-ABL transformation or associated with inhibition of BCR-ABL signaling.
Imatinib-resistant clonal variants derived from imatinibsensitive cell lines were also treated with ON012380 and other inhibitors to assess target-specific effects and antitumor activity. Table 1 ). K562R cells are BCR-ABL kinase mutation negative but overexpress Lyn kinase. 3, 4 As shown in Figure 2a (top), imatinib dose-dependently reduced the growth and survival of K562 and BV-173 cells (IC50 B0.2 mM) but had minimal effects on BV-173R or K562R cell survival (IC50 45 mM). Dasatinib dose-dependently reduced the viability of K562, K562R and BV-173 cells but had 100-fold less activity against BV-173R cells (dasatinib IC50 B0.02 mM in BV-173 vs B2 mM in BV-173R). Dasatinib concentrations necessary to reduce growth and survival of T315I-expressing BV-173R cells are not likely to be clinically achieved by current dasatinib regimens. 5 In
